Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment of Patients with Metastatic NSCLC By Ogkologos - April 14, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 3475A-D77 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC September 29, 2022 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... June 30, 2021 Load more HOT NEWS Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... Women in Science: Celebrating with our Women of Influence initiative Death Rates from Lung Cancer will Fall Overall in the EU... New Study Finds Dogs Can Sniff Out Lung Cancer — And...
